Hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation: incidence, risk factors, and outcome

被引:58
作者
Lee, S. H. [2 ]
Yoo, K. H. [2 ]
Sung, K. W. [2 ]
Koo, H. H. [2 ]
Kwon, Y. J. [3 ]
Kwon, M. M. [3 ]
Park, H. J. [3 ]
Park, B-K [3 ]
Kim, Y. Y. [4 ]
Park, J. A. [5 ]
Im, H. J. [5 ]
Seo, J. J. [5 ]
Kang, H. J. [1 ]
Shin, H. Y. [1 ]
Ahn, H. S. [1 ]
机构
[1] Seoul Natl Univ, Coll Med, Dept Pediat, Seoul 110744, South Korea
[2] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Pediat, Seoul, South Korea
[3] Natl Canc Ctr, Pediat Oncol Clin, Goyang, South Korea
[4] Korea Childhood Leukemia Fdn, Seoul, South Korea
[5] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Pediat, Seoul, South Korea
关键词
veno-occlusive disease; hematopoietic stem cell transplantation; prophylaxis; lipid microspheres-containing prostaglandin E1; ferritin; BONE-MARROW-TRANSPLANTATION; TOTAL-BODY IRRADIATION; HIGH-DOSE CHEMOTHERAPY; LIPID MICROSPHERES; CONTINUOUS-INFUSION; LIVER TOXICITY; PROSTAGLANDIN-E1; PREVENTION; BUSULFAN; HEPARIN;
D O I
10.1038/bmt.2009.349
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
Four hundred and sixty-seven hematopoietic stem cell transplantations (HSCTs) (217 autologous and 250 allogeneic HSCT) were performed in 374 children at four pediatric HSCT centers in Korea from January 2005 to December 2007. Among 467 transplants, veno-occlusive disease (VOD) developed in 72 transplants (15.4%) at a median of 10 days after HSCT. Multivariate analysis showed that BU or TBI-containing regimen (P = 0.002), VOD prophylaxis without lipo-prostaglandin E1 (PGE1) (P = 0.012), number of previous HSCT (P = 0.014), and pretransplant serum ferritin (P = 0.018) were independent risk factors for developing VOD. Mean serum ferritin levels were significantly higher in HSCT with VOD (2109.6 +/- 2842.5 ng/ml) than in HSCT without VOD (1315.9 +/- 1094.4 ng/ml) (P < 0.001). The relative risk of death within 100 days of HSCT in transplants with VOD compared with transplants without VOD was 3.39 (confidence interval: 1.78-6.45). Our results suggest that lipo-PGE1 might have a protective effect against the development of VOD, and pretransplant serum ferritin could act as a risk factor for VOD. A larger prospective study is needed to confirm a possible role of lipo-PGE1 and iron chelation therapy in reducing the incidence of VOD. Bone Marrow Transplantation (2010) 45, 1287-1293; doi: 10.1038/bmt.2009.349; published online 14 December 2009
引用
收藏
页码:1287 / 1293
页数:7
相关论文
共 44 条
[1]   Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation [J].
Armand, Philippe ;
Kim, Haesook T. ;
Cutler, Corey S. ;
Ho, Vincent T. ;
Koreth, John ;
Alyea, Edwin P. ;
Soiffer, Robert J. ;
Antin, Joseph H. .
BLOOD, 2007, 109 (10) :4586-4588
[2]  
ATTAL M, 1992, BLOOD, V79, P2834
[3]   Incidence, survival and risk factors for the development of veno-occlusive disease in pediatric hematopoietic stem cell transplant recipients [J].
Barker, CC ;
Butzner, JD ;
Anderson, RA ;
Brant, R ;
Sauve, RS .
BONE MARROW TRANSPLANTATION, 2003, 32 (01) :79-87
[4]   A PHASE-I PHASE-II STUDY OF PROSTAGLANDIN-E1 FOR THE PREVENTION OF HEPATIC VENOOCCLUSIVE DISEASE AFTER BONE-MARROW TRANSPLANTATION [J].
BEARMAN, SI ;
SHEN, DD ;
HINDS, MS ;
HILL, HA ;
MCDONALD, GB .
BRITISH JOURNAL OF HAEMATOLOGY, 1993, 84 (04) :724-730
[5]   VENOOCCLUSIVE DISEASE OF THE LIVER - DEVELOPMENT OF A MODEL FOR PREDICTING FATAL OUTCOME AFTER MARROW TRANSPLANTATION [J].
BEARMAN, SI ;
ANDERSON, GL ;
MORI, M ;
HINDS, MS ;
SHULMAN, HM ;
MCDONALD, GB .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (09) :1729-1736
[6]  
BEARMAN SI, 1990, BONE MARROW TRANSPL, V5, P407
[7]   Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications [J].
Beelen, DW ;
Trenschel, R ;
Casper, J ;
Freund, M ;
Hilger, RA ;
Scheulen, ME ;
Basara, N ;
Fauser, AA ;
Hertenstein, B ;
Mylius, HA ;
Baumgart, J ;
Pichlmeier, U ;
Hahn, JR ;
Holler, E .
BONE MARROW TRANSPLANTATION, 2005, 35 (03) :233-241
[8]  
BRUGIERES L, 1988, BONE MARROW TRANSPL, V3, P53
[9]   Risk factors for hepatic veno-occlusive disease: a retrospective unicentric study in 116 children autografted after a high-dose BU-thiotepa regimen [J].
Cacchione, A. ;
LeMaitre, A. ;
Couanet, D. Valteau ;
Benhamou, E. ;
Amoroso, L. ;
Simonnard, N. ;
Hartmann, O. .
BONE MARROW TRANSPLANTATION, 2008, 42 (07) :449-454
[10]  
Carreras E, 1998, BLOOD, V92, P3599